These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 9054471

  • 1. Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients.
    Kohno M, Murakawa K, Yasunari K, Yokokawa K, Horio T, Kano H, Minami M, Yoshikawa J.
    Metabolism; 1997 Mar; 46(3):287-91. PubMed ID: 9054471
    [Abstract] [Full Text] [Related]

  • 2. Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients.
    Miossec P, Zkhiri F, Pariès J, David-Dufilho M, Devynck MA, Valensi PE.
    Diabet Med; 1999 May; 16(5):424-30. PubMed ID: 10342343
    [Abstract] [Full Text] [Related]

  • 3. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P, Echevaría-Vázquez D, Petrov V.
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [Abstract] [Full Text] [Related]

  • 4. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 5. Effects of simvastatin and pravastatin on peroxidation of erythrocyte plasma membrane lipids in patients with type 2 hypercholesterolemia.
    Koter M, Franiak I, Broncel M, Chojnowska-Jezierska J.
    Can J Physiol Pharmacol; 2003 May; 81(5):485-92. PubMed ID: 12774855
    [Abstract] [Full Text] [Related]

  • 6. Effect of plasma cholesterol reduction by pravastatin on the functional properties of forearm arteries in hypercholesterolemic patients.
    Baldassarre D, Busnach G, Amato M, Pazzucconi F, Sirtori CR.
    Nutr Metab Cardiovasc Dis; 1999 Jun; 9(3):108-17. PubMed ID: 10464783
    [Abstract] [Full Text] [Related]

  • 7. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.
    Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D.
    Circulation; 1995 Dec 01; 92(11):3172-7. PubMed ID: 7586300
    [Abstract] [Full Text] [Related]

  • 8. Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin.
    Porreca E, Di Febbo C, Baccante G, Di Nisio M, Cuccurullo F.
    J Am Coll Cardiol; 2002 Jun 05; 39(11):1752-7. PubMed ID: 12039487
    [Abstract] [Full Text] [Related]

  • 9. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
    Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK.
    Circulation; 2017 Nov 14; 136(20):1878-1891. PubMed ID: 28877913
    [Abstract] [Full Text] [Related]

  • 10. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect.
    Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, Cohen AM, Fallon JT, Badimon JJ, Ambrose JA.
    Thromb Haemost; 2000 May 14; 83(5):688-92. PubMed ID: 10823263
    [Abstract] [Full Text] [Related]

  • 11. Phytosterols dissolved in diacylglycerol oil reinforce the cholesterol-lowering effect of low-dose pravastatin treatment.
    Takeshita M, Katsuragi Y, Kusuhara M, Higashi K, Miyajima E, Mizuno K, Mori K, Obata T, Ohmori R, Ohsuzu F, Onodera Y, Sano J, Sawada S, Tabata S, Tokimitsu I, Tomonobu K, Yamashita T, Yasukawa T, Yonemura A, Nakamura H.
    Nutr Metab Cardiovasc Dis; 2008 Sep 14; 18(7):483-91. PubMed ID: 17964767
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
    Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R, Pravastatin in Chronic Liver Disease Study Investigators.
    Hepatology; 2007 Nov 14; 46(5):1453-63. PubMed ID: 17668878
    [Abstract] [Full Text] [Related]

  • 13. [The comparison in vitro the effects of pravastatin and quercetin on the selected structural parameters of membrane erythrocytes from patients with hypercholesterolemia].
    Broncel M, Franiak I, Koter-Michalak M, Duchnowicz P, Chojnowska-Jezierska J.
    Pol Merkur Lekarski; 2007 Feb 14; 22(128):112-6. PubMed ID: 17598654
    [Abstract] [Full Text] [Related]

  • 14. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults.
    Janatuinen T, Laaksonen R, Vesalainen R, Raitakari O, Lehtimäki T, Nuutila P, Knuuti J.
    J Cardiovasc Pharmacol; 2001 Oct 14; 38(4):561-8. PubMed ID: 11588526
    [Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl.
    Glasser SP, DiBianco R, Effron BA, Faas F, Germino FW, Shane LE, Unger AH, Staggers JE.
    Am J Cardiol; 1996 Jan 01; 77(1):83-5. PubMed ID: 8540464
    [Abstract] [Full Text] [Related]

  • 16. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG.
    Am J Cardiol; 2003 Mar 06; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [Abstract] [Full Text] [Related]

  • 17. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test.
    Saito Y, Goto Y, Nakaya N, Hata Y, Homma Y, Naito C, Hayashi H, Ito H, Yamamoto M, Takeuchi I.
    Atherosclerosis; 1988 Aug 06; 72(2-3):205-11. PubMed ID: 3145746
    [Abstract] [Full Text] [Related]

  • 18. Statins improve visual field alterations related to hypercholesterolemia.
    Alcalá A, Jansen S, Téllez T, Gómez-Huelgas R, Pérez O, Egido J, Farkouh ME.
    Atherosclerosis; 2010 Apr 06; 209(2):510-4. PubMed ID: 19892351
    [Abstract] [Full Text] [Related]

  • 19. Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.
    Lee WJ, Lee WL, Tang YJ, Liang KW, Chien YH, Tsou SS, Sheu WH.
    Clin Chim Acta; 2008 Apr 06; 390(1-2):49-55. PubMed ID: 18201563
    [Abstract] [Full Text] [Related]

  • 20. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
    Castaño G, Más R, Arruzazabala ML, Noa M, Illnait J, Fernández JC, Molina V, Menéndez A.
    Int J Clin Pharmacol Res; 1999 Apr 06; 19(4):105-16. PubMed ID: 10939028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.